Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Human papilloma virus (HPV) vaccines and vaccination strategy

Written by | 11 Mar 2021

Interview and article by Christine Clark Dr Peter English, a consultant in communicable disease control describes the UK HPV vaccination strategy and the associated issues. Dr Peter English,… read more.

Human papilloma virus (HPV) and cervical cancer

Written by | 10 Mar 2021

Interview and article by Christine Clark Cervical cancer accounts for about 850 cancer deaths in the UK every year – more than two every day – and yet… read more.

Reduced hormone supply in pregnant mothers linked to ADHD in their children

Written by | 10 Nov 2020

Low levels of key, body-regulating chemicals in mothers during the first three months of pregnancy may interfere with the baby’s brain development, a large American study shows.

Fecal transplantation can restore the gut microbiota of C-section babies

Written by | 5 Nov 2020

The human gut contains a diverse ecosystem of microbes: mainly bacteria, as well as viruses and fungi, termed the gut microbiota. Recent years have shown that the gut… read more.

FDA approves Phexxi the first and only non-hormonal prescription gel for the prevention of pregnancy.-Evofem Biosciences, Inc.

Written by | 24 May 2020

Evofem Biosciences, Inc. announced that the FDA has approved Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive… read more.

Myovant Sciences announces publication of abstracts detailing efficacy and safety from phase III LIBERTY studies in uterine fibroids in Obstetrics & Gynecology journal.

Written by | 28 Apr 2020

Myovant Sciences announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety findings from the Phase III LIBERTY 1 and 2 studies… read more.

Myovant Sciences announces publication of abstracts detailing efficacy and safety from phase III LIBERTY studies in uterine fibroids in Obstetrics & Gynecology journal.

Written by | 28 Apr 2020

Myovant Sciences announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety findings from the Phase III LIBERTY 1 and 2 studies… read more.

Myovant Sciences announces publication of abstracts detailing efficacy and safety from phase III LIBERTY studies in uterine fibroids in Obstetrics & Gynecology journal.

Written by | 28 Apr 2020

Myovant Sciences announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety findings from the Phase III LIBERTY 1 and 2 studies… read more.

Myovant Sciences announces publication of abstracts detailing efficacy and safety from phase III LIBERTY studies in uterine fibroids in Obstetrics & Gynecology journal.

Written by | 28 Apr 2020

Myovant Sciences announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety findings from the Phase III LIBERTY 1 and 2 studies… read more.

Myovant Sciences announces publication of abstracts detailing efficacy and safety from phase III LIBERTY studies in uterine fibroids in Obstetrics & Gynecology journal.

Written by | 28 Apr 2020

Myovant Sciences announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety findings from the Phase III LIBERTY 1 and 2 studies… read more.

Myovant Sciences announces publication of abstracts detailing efficacy and safety from phase III LIBERTY studies in uterine fibroids in Obstetrics & Gynecology journal.

Written by | 28 Apr 2020

Myovant Sciences announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety findings from the Phase III LIBERTY 1 and 2 studies… read more.

ECCO 2018: Novel treatments in IBD

Written by | 11 Feb 2018

The current research and development pipeline of novel biologic therapies and small molecule drugs promises improved efficacy and safety in the treatment of IBD in the near future…. read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.